Abstract 170P
Background
The interaction between gastric cancer (GC) tumor cells and tumor microenvironment could impact on the response to conventional chemotherapies (CT). The aim of this study was to obtain a wide transcriptomic profile with spatial resolution of tissue samples from locally advanced GC patients (pts) who present extremely different response to neoadjuvant CT (NCT).
Methods
Nanostring GeoMx Digital Spatial Profiler (DSP) was performed on pre-therapy biopsies and matched surgical specimens from 6 patients who received NCT. Three pts reached a complete pathological response (CRs), the remaining do not respond (NRs). Regions of interest were visualized on FFPE sections based on immunofluorescent staining for nuclear (DNASyto13), tumor (Pan-cytokeratin) and immune cell (CD45) compartments. Expression levels of more 1,800 genes were evaluated by using the Cancer Transcriptome Atlas (CTA) panel. Transcripts counts were generated using NextSeq 550 instrument (Illumina) and analysed by DSP analysis suite (Nanostring). Effector memory T cells were analysed by immunoistochemistry using CD45RO antibody.
Results
Cells in the tumor compartment of CRs presented an enrichment of deregulated pathways involved in extracellular matrix (ECM) organization and degradation, whereas key pathways involved in cell junction organization, interferon signaling and cell-cell communication were upregulated in NRs. Higher levels of intratumoral CD45RO staining was observed in CRs. A high number of pathways, mainly related to the ECM remodelling and cell surface interaction, as for tumoral cells, resulted upregulated in immune compartment of CRs. Conversely, lymphocytes in NRs were characterized by enrichment in genes involved in the signaling by B cell receptor and generation of second messenger molecules.
Conclusions
A comprehensive characterization of the expression profile of tumor and immune cells showed the contribution of both compartments in the chemosensitivity, mainly through the regulation of ECM organization and remodeling. DSP-based analyses will help to decipher the different responses of GC patients to chemotherapy, enabling the identification of potential biomarker signatures.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\".
Funding
Italian Ministry of Health within the ERAPerMed Project GRAMMY (ERP-2019-23671108; GRAMMY, 2019-275).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
141P - An unconditionally dynamic culture system for cancer stem cell
Presenter: Ya-Juan Zhu
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Lipidomic signature in response to omega-3 fatty acids and γ-linolenic acid supplementation in breast cancer patients receiving aromatase inhibitors
Presenter: Vesna Vucic
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
Presenter: Simone Rota
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Is it time to incorporate next generation sequencing of body fluids for detection of circulating tumor DNA (ctDNA) alterations?
Presenter: Aditya Shreenivas
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Unveiling the molecular landscape of head and neck cancer: Pathway dysregulations and potential therapeutic targets
Presenter: Rajeev Vijayakumar
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - ESR1 fusions as potential mechanism of resistance to endocrine therapy in metastatic breast cancer
Presenter: Sewanti Limaye
Session: Cocktail & Poster Display session
Resources:
Abstract
147P - Clinical characteristics and outcomes in non-small cell lung cancer patients harboring rare mutations: A single center real-world data
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Diversity of genomic mechanisms of resistance to endocrine therapy in ER+ breast cancer
Presenter: Prithika Sritharan
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Assessing treatment options for gynaecological cancers (GC) using next-generation sequencing (NGS): A real-world analysis
Presenter: Álvaro García
Session: Cocktail & Poster Display session
Resources:
Abstract
150P - Prevalence of DPYD variants in 1478 cancer patients receiving fluoropyrimidine chemotherapy: A real-world data analysis
Presenter: Bahaaeldin Baraka
Session: Cocktail & Poster Display session
Resources:
Abstract